A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

J Viral Hepat. 1996 Jul;3(4):211-5. doi: 10.1111/j.1365-2893.1996.tb00098.x.

Abstract

This is the first double-blind controlled study of famciclovir, an oral antiviral agent, as potential therapy for chronic hepatitis B virus (HBV) carries. A fall of more than 90% in HBV DNA levels was noted in six of 11 evaluable patients treated with a 10 day course of oral famciclovir. Further studies with more prolonged therapy are ongoing.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • 2-Aminopurine / analogs & derivatives*
  • 2-Aminopurine / therapeutic use
  • Adolescent
  • Adult
  • Antiviral Agents / therapeutic use*
  • Carrier State
  • Chronic Disease
  • DNA, Viral / analysis
  • Double-Blind Method
  • Famciclovir
  • Female
  • Hepatitis B / drug therapy*
  • Hepatitis B virus / genetics
  • Hepatitis B virus / physiology*
  • Humans
  • Male
  • Middle Aged
  • Virus Replication*

Substances

  • Antiviral Agents
  • DNA, Viral
  • 2-Aminopurine
  • Famciclovir